Shionogi's naldemedine performs well in first COMPOSE Phase III
This article was originally published in Scrip
Shionogi's naldemedine (S-297995), an investigational peripherally acting mu-opioid receptor antagonist, has met primary and secondary endpoints in a phase III study for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain receiving opioid therapy.
You may also be interested in...
With oral naldemedine joining Purdue's pain portfolio, the company will look for ways to foster communication between patients and doctors about treatment for opioid-induced constipation.
A complete response letter from the FDA in June knocked Intercept’s stock price down to 2014 levels, but perhaps the regulator is sending wider messages about NASH.
A selection of features you might have missed from the first six months of 2020, covering key topics from COVID-19 strategies in medtech to an analysis of pipeline focus areas across the pharma sector. Click on each section to get the full story behind the data.